| Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. | |
| | |
MedLine Citation:
|
PMID: 22224712 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Eur J Clin Invest 2011 ABSTRACT: Background Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidaemia (FCH), familial hypercholesterolaemia (FH) and coronary artery disease (CAD). Scarce data are available on fasting plasma apolipoprotein (apo) B48 levels in relation to these conditions and atherosclerosis. Design Treated patients with FCH (18), FH (20), T2DM (26), CAD (65), T2DM with CAD (T2DM/CAD) (28) and 33 healthy controls were included. Intima-media thickness (IMT) measurements were carried out to investigate subclinical atherosclerosis. Results LDL-C and total apoB were lowest in patients with T2DM/CAD owing to the more frequent use of lipid-lowering medication. Fasting plasma apoB48 was elevated in patients with FCH (11·38 ± 1·50 mg/L) and T2DM/CAD (9·65 ± 1·14 mg/L) compared with the other groups (anova, P < 0·01). CAD patients (8·09 ± 0·57 mg/L) had higher apoB48 levels than controls (5·74 ± 0·55 mg/L) and FH patients (5·40 ± 0·51 mg/L) (P = 0·02). IMT was highest in subjects with T2DM/CAD (0·77 ± 0·03 mm) (P < 0·01). The lowest IMT was measured in controls (0·56 ± 0·02 mm) and FCH patients (0·60 ± 0·03 mm). In the total group, the best association for apoB48 was found with fasting triglyceride (Pearson's r = 0·72, P < 0·001). In the subjects not using statins (n = 74), the best correlation was found with IMT (r = 0·52; P < 0·001), whereas total apoB was not associated with IMT (r = 0·20, P = 0·12). Conclusions ApoB48 concentrations are highest in patients with FCH and in atherosclerotic subjects with T2DM. In patients not using statins, the surrogate atherosclerosis marker IMT correlates best with apoB48, suggesting that fasting apoB48 may help to detect subjects at risk. |
| | |
Authors:
|
Arash Alipour; Pedro Valdivielso; Jan Willem F Elte; Hans W Janssen; Jose Rioja; Noëlle van der Meulen; Rob van Mechelen; Tjin L Njo; Pedro González-Santos; Arie P Rietveld; Manuel Castro Cabezas |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-2 |
Journal Detail:
|
Title: European journal of clinical investigation Volume: - ISSN: 1365-2362 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2012-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0245331 Medline TA: Eur J Clin Invest Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation. |
Affiliation:
|
Department of Internal Medicine, Center for Diabetes and Vascular Medicine, St Franciscus Gasthuis, Rotterdam, The Netherlands Lipids Unit, Department of Internal Medicine, Hospital Virgen de la Victoria, Malaga, Spain Department of Clinical Chemistry, St Franciscus Gasthuis, Rotterdam, The Netherlands CIMES, Department of Medicine & Dermatology, Universidad de Malaga, Spain Department of Cardiology, St Franciscus Gasthuis, Rotterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vacuolar glyphosate-sequestration correlates with glyphosate resistance in ryegrass (Lolium spp.) fr...
Next Document: One-step preparation of uniform cane-ball shaped water-swellable microgels containing poly(N-vinyl f...